This FAQ explains how aseptic processing, contamination control, and validation protect patients amid sterile injectable failures.
|Articles|July 15, 2015
EMD Millipore Introduces Flexible Single-Use Bioreactor
Author(s)BioPharm International Editors
The Mobius 2000-L single-use bioreactor from EMD Millipore offers configurable software, hardware, and single-use Flexware assemblies for suspension and adherent cell-culture applications.
Advertisement
The Mobius 2000-L single-use bioreactor from EMD Millipore, the Life Science business of Merck KGaA, joins the Mobius stirred tank bioreactor portfolio that now ranges from 3 to 2000 L. Features include configurable software, hardware, and single-use Flexware assemblies for suspension and adherent cell-culture applications.
The bioreactor features the industry's first pull-out drawer and self-deploying bag, which makes Flexware assembly installation and inflation safe and easy. This design minimizes operator intervention and requires no hoist during Flexware assembly installation and removal. A patent-pending baffle design creates homogenous mixing. The 5:1 turndown ratio allows users to inoculate and harvest at lower volumes, creating a wider, more flexible process window for seeding, growth, and collection strategies.
The bioreactor includes an external SensorReady loop connected to the Flexware assembly to provide greater flexibility for process monitoring and control. Unlike traditional bioreactors in which sensors are inserted into the Flexware assembly, the SensorReady loop enables users to incorporate additional sensors without modifying the Flexware assembly.
The Mobius bioreactor can be supplied as a fully integrated system with intuitive GMP-compliant software that reduces the learning curve for operators and allows for easy integration into plant automation strategies. The automation is simple and enables users to easily customize and control their processes. For customers with plant-wide common automation strategies, the single-use bioreactor can be integrated into third-party automation platforms.
Source:
Advertisement
Related to this article
Bimekizumab-bkzx (Bimzelx) produced ACR50 joint responses in 54.9% of psoriatic arthritis patients at week 24 vs 43.8% with risankizumab.
VG801 gene therapy improved vision through 12 months in a Stargardt disease trial as VeonGen aligned with FDA on its pivotal phase 3 design.
Matt Trupo, Richard Jaenisch, and Brian Drapeau explore how AI advances biological insights, drug-target discovery, and supply chains.
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
Aldevron and IDT added PE Ultra prime editor mRNA and 6 ABE8e base editor mRNAs to help researchers edit DNA without double-strand breaks.
In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development
3
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
4
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
5